The US Food and Drug Administration has announced the approval of a new drug for Type 2 diabetes, Tradjenta (linagliptin). The drug was developed by Boehringer Ingelheim which has a commercialisation deal for the drug with Eli Lilly. ---Subscribe to MedNous to access this article--- Regulation & Policy Company News
